trial

The Effects of Rimonabant, on Weight and Metabolic Risk Factors

NCTId NCT00547118
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 2 · Terminated
Enrollment 17 (actual)
Sponsored by University of Maryland, Baltimore County
Primary completion 2009-03
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 2
Status
Terminated
Enrollment
17 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Quadruple
Start
2007-11
Primary completion
2009-03
Eligibility
ALL · 18 Years · 55 Years

Interventions & indications

Drugs
Rimonabant

Sponsors

University of Maryland, Baltimore CountyLead Sponsor
National Institute on Drug Abuse (NIDA)Collaborator

Investigators

1
Robert W Buchanan, MDPrincipal Investigator

Sites

4 total
Baltimore, United StatesBaltimore, United StatesBaltimore, United StatesCatonsville, United States

Linked catalysts

1
The Effects of Rimonabant, on Weight and Metabolic Risk Factors — primary completion2009-03

Facts & assertions

4 sourced
Enrollment
17
Phase
PHASE2
Primary Completion Date
2009-03
Status
TERMINATED
relationships
The graph out of here
drug
Rimonabant
drug
lead_sponsor
University of Maryland, Baltimore County
company
collaborator
National Institute on Drug Abuse (NIDA)
company
indication
Smoking
indication
Obesity
indication
Schizoaffective Disorder
indication
investigator
Robert W Buchanan, MD
person